-
公开(公告)号：US4761400A
公开(公告)日：1988-08-02
申请号：US816617
申请日：1986-01-06
申请人： Bernard J. M. Doat , Jean-Francois J. Letavernier , Gilbert G. Aubard , Jean B. Llull , Alain P. Calvet , Jean-Louis Junien
发明人： Bernard J. M. Doat , Jean-Francois J. Letavernier , Gilbert G. Aubard , Jean B. Llull , Alain P. Calvet , Jean-Louis Junien
CPC分类号： A61K31/70 , A61K47/36 , A61K9/0056
摘要： Lactulose-based laxative composition which is in the form of a jelly with a viscosity at 20.degree. C. measured on the Brookfield viscosimeter between 15,000 and 30,000 centipoises, a refractive index at 20.degree. C. between 1.430 and 1.445 and a pH between 3 and 4.
摘要翻译： 乳果糖基的泻药组合物为粘稠度为20℃的果冻形式，在Brookfield粘度计上测定为15,000至30,000厘泊，折射率为20℃，介于1.430和1.445之间，pH在3和 4。
-
公开(公告)号：US20090118306A1
公开(公告)日：2009-05-07
申请号：US11920141
申请日：2006-05-10
IPC分类号： A61K31/03 , C12N5/10 , A61K31/4439 , A61K31/155 , A61K31/445 , A61K31/4965 , A61K31/18 , A61K31/451 , A61K31/351 , A61K31/426 , A61K31/195 , A61P3/10
CPC分类号： A61K31/00 , A61K31/18 , A61K31/195 , Y10S514/866
摘要： The present invention generally relates to a novel therapeutical use of liver X receptor (LXR) agonsits. More specifically, the present invention relates to the use of LXR agonist for the preparation of a medicament useful for the treatment and/or the prevention of a disease associated with beta cells degeneration, such as diabetes, and a method for increasing ex vivo viability of pancreatic islet cells, comprising contacting said islet cells with a LXR agonist.
摘要翻译： 本发明一般涉及肝X受体（LXR）治疗的新型治疗用途。 更具体地说，本发明涉及LXR激动剂在制备可用于治疗和/或预防与β细胞变性相关的疾病（例如糖尿病）的药物中的用途，以及增加体内存活力的方法 胰岛细胞，包括使所述胰岛细胞与LXR激动剂接触。
-
公开(公告)号：US06844180B2
公开(公告)日：2005-01-18
申请号：US09976674
申请日：2001-10-12
IPC分类号： G01N33/50 , A61K45/00 , A61P3/14 , A61P7/02 , A61P9/10 , A61P9/12 , A61P17/06 , A61P21/04 , A61P25/08 , A61P25/14 , A61P31/12 , A61P35/02 , A61P43/00 , C07K16/40 , C12N1/21 , C12N5/10 , C12N9/48 , C12N9/64 , C12N15/09 , C12Q1/37 , G01N33/15 , G01N33/53 , G01N33/566 , C12N9/62 , C07H21/04 , C12N1/20 , C12N5/00 , C12N15/00
CPC分类号： C12N9/48 , C12N2799/026
摘要： Novel proteins or polypeptides having significant sequence homology to DPPIV, nucleic acids coding therefor, cells which have been modified with such nucleic acid so as to express these proteins, antibodies to these proteins, screening methods for the discovery of new therapeutic agents which are inhibitors of the activity of these proteins or of related proteins, and therapeutic agents discovered by such screening methods, as well as new therapeutic treatments, are all provided.
摘要翻译： 与DPPIV具有显着序列同源性的新型蛋白质或多肽，其编码的核酸，已经用此类核酸修饰以表达这些蛋白质的细胞，对这些蛋白质的抗体，用于发现作为这些蛋白质的抑制剂的新治疗剂的筛选方法 这些蛋白质或相关蛋白质的活性以及通过这种筛选方法发现的治疗剂以及新的治疗方法都被提供。
-
24.发明授权Nucleic acids encoding dog gastric lipase and their use for the production of polypeptides 失效编码狗胃脂肪酶的核酸及其用于产生多肽的用途
公开(公告)号：US5807726A
公开(公告)日：1998-09-15
申请号：US227108
申请日：1994-04-13
IPC分类号： C12N15/09 , A61K38/00 , A61K38/46 , A61P3/06 , C07H21/04 , C12N1/21 , C12N9/20 , C12N15/55 , C12N15/63
摘要： The present invention relates to dog gastric lipase as obtained by genetic engineering as well as to the nucleotide sequence encoding this recombinant DGL. It also relates to the use of this recombinant DGL for the production of pharmaceutical compositions intended especially for the treatment of pathologies linked to the insufficiency, or even the absence, of secretion of lipases in the body of an individual.
摘要翻译： 本发明涉及通过遗传工程获得的狗胃脂肪酶以及编码该重组DGL的核苷酸序列。 它还涉及这种重组DGL用于制备药物组合物的用途，该药物组合物特别用于治疗与个体身体中脂肪酶分泌不足或甚至不存在相关的病理学。
-
公开(公告)号：US5389686A
公开(公告)日：1995-02-14
申请号：US91691
申请日：1993-07-13
IPC分类号： C07C217/48 , A61K31/135
CPC分类号： C07C217/48
摘要： Process for the treatment of painful syndromes, especially local and/or visceral, consisting in the parenteral or topical administration of a therapeutically effective quantity of the (-) tartrate of (+)-(R)-1-[(3,4,5-trimethoxy)benzyloxymethyl]-1-phenyl-N,N-dimethyl-n-propylamine.
摘要翻译： 用于治疗疼痛综合征，特别是局部和/或内脏的方法，其组合在肠胃外或局部施用治疗有效量的（+） - （R）-1 - [（3,4,5-三甲基 - 5-三甲氧基）苄氧基甲基] -1-苯基-N，N-二甲基 - 正丙胺。
-
26.发明授权Use of fedotozine in the treatment of functional states of intestinal obstructions 失效使用fedotozine治疗肠梗阻功能状态
公开(公告)号：US5362756A
公开(公告)日：1994-11-08
申请号：US937127
申请日：1992-08-31
IPC分类号： C07C217/48 , A61K31/135
CPC分类号： C07C217/48
摘要： A process for inhibiting functional ileus in a patient, which consists of administering a therapeutically effective dose of (+)-1-1[(3,4,5-trimethoxy)benzyloxymethyl]-1-phenyl-N,N dimethylpropylamine or the addition salt thereof with (-)-tartaric acid is disclosed.
摘要翻译： 一种用于抑制患者功能性肠梗阻的方法，其包括施用治疗有效剂量的（+） - 1-1 [（3,4,5-三甲氧基）苄氧基甲基] -1-苯基-N，N二甲基丙胺或加成 公开了其与（ - ） - 酒石酸的盐。
-
27.发明授权Cycloalkylalkylamines which are sigma-receptor ligands and their application in therapy 失效作为σ-受体配体的环烷基烷基胺及其在治疗中的应用
公开(公告)号：US5326784A
公开(公告)日：1994-07-05
申请号：US99299
申请日：1993-07-29
IPC分类号： A61K31/13 , A61K31/15 , A61K31/275 , A61K31/35 , A61K31/352 , A61K31/357 , A61P1/04 , A61P25/00 , A61P25/02 , A61P25/18 , C07C211/38 , C07C215/42 , C07C225/18 , C07C251/44 , C07D311/22 , C07D311/32 , C07D311/68 , C07D317/72 , C07D493/10 , A61K31/135 , C07C211/19 , C07D311/74
CPC分类号： C07D317/72 , C07C215/42 , C07C225/18 , C07C251/44 , C07D311/22 , C07D493/10 , C07C2101/02 , C07C2101/04 , C07C2101/14 , C07C2102/08 , C07C2102/10 , C07C2102/12
摘要： New cycloalkylalkylamines which are sigma-receptor ligands of formule (I) ##STR1## in which: R.sub.1 is H or lower alkyl; X and Y are H, OH, lower alkyl, lower alkoxy, halogen or nitrile; V.sub.1 and V.sub.2 together form a double bond attached to an oxygen atom or to a hydroxyimino radical, or are linked as an ethylenedioxy chain; A represents a valency bond, an oxygen atom, a methylene or an ethylene group; m is equal to 0, 1 or 2; n has the value of an integer from 1 to 5. Psychotropic drug which is also useful in gastroenterology.
摘要翻译： 新的环烷基烷基胺，其是式（I）的σ-受体配体。其中：R 1是H或低级烷基; X和Y是H，OH，低级烷基，低级烷氧基，卤素或腈; V1和V2一起形成连接到氧原子或羟基亚氨基的双键，或者作为亚乙二氧基链连接; A表示价键，氧原子，亚甲基或亚乙基; m等于0,1或2; n具有从1到5的整数的值。精神药物也可用于胃肠病学。
-
28.发明授权Propanamines, their pharmacological properties and their application as an antidiarrheal 失效丙胺，其药理特性及其作为止泻药的应用
公开(公告)号：US5236947A
公开(公告)日：1993-08-17
申请号：US899712
申请日：1992-06-17
IPC分类号： C07C205/04 , C07C205/09 , C07C205/32 , C07C205/45 , C07C217/72 , C07C225/16 , C07D317/28
CPC分类号： C07C225/16 , C07C205/04 , C07C205/09 , C07C205/32 , C07C205/45 , C07C217/72 , C07D317/28
摘要： The present invention relates to propanamines of general formula (I) ##STR1## in which: R1 is a phenyl radical optionally mono-, di- or trisubstituted in an identical or different manner with halogen atoms, or lower alkyl, lower haloalkyl or lower alkoxy radicals;R2 is a lower alkyl radical,R3 and R4 are a hydrogen atom or a lower alkyl, lower alkenyl or lower cycloalkyalkyl radical,R5 is a 5-to 7-membered cycloalkyl radical or a phenyl radical, andW represents a heterocycle .dbd.C[Q--(CH.sub.2).sub.n --Q] in which Q is an oxygen or sulfur atom and n is 2 or 3,and their acid addition salts with pharmaceutically acceptable acids. The invention also relates to antidiarrheal pharmaceutical compositions comprising the claimed propanamines.
摘要翻译： 本发明涉及通式（I）的丙胺，其中：R 1是任选地以与卤素原子相同或不同的方式单，二或三取代的苯基，或低级烷基低级卤代烷基 或低级烷氧基; R2是低级烷基，R3和R4是氢原子或低级烷基，低级烯基或低级环烷基，R5是5-至7-元环烷基或苯基，W表示杂环= C [ Q-（CH2）nQ]其中Q是氧或硫原子，n是2或3，以及它们与药学上可接受的酸的酸加成盐。 本发明还涉及包含所要求保护的丙胺的止泻药物组合物。
-
公开(公告)号：US5082937A
公开(公告)日：1992-01-21
申请号：US584150
申请日：1990-09-18
IPC分类号： A61K31/55 , A61P1/04 , A61P3/04 , A61P25/00 , A61P25/04 , A61P43/00 , C07D471/06 , C07D487/06
CPC分类号： C07D471/06 , C07D487/06
摘要： Benzodiazepines of formula ##STR1## in which R.sup.9 is hydrogen or chlorine, R10 is phenyl, possibly substituted, R11 is hydrogen, R12 is oxygen or sulphur, R13 is an NH group, Ar is aromatic or heteroaromatic comprising one or more rings and in which, in particular, A is an ethylene or trimethylene bridge; e is 1 or 2; which are gastrin antagonists and/or central antagonists of cholecystokinin.
摘要翻译： 式（I）的苯并二氮杂其中R 9为氢或氯，R 10为苯基，可能被取代，R 11为氢，R 12为氧或硫，R 13为NH基，Ar为包含一个或多个环的芳族或杂芳族 其中A特别是乙烯或三亚甲基桥; e为1或2; 其为胃泌素拮抗剂和/或胆囊收缩素的中枢拮抗剂。
-
30.发明申请Use of a PPARalpha Agonist and Metformin for Decreasing the Serum Triglycerides 审中-公开使用PPARα激动剂和二甲双胍降低血清甘油三酯公开(公告)号：US20100144874A1
公开(公告)日：2010-06-10
申请号：US12705155
申请日：2010-02-12
申请人： Jean-Louis Junien , Alan Edgar , Evelyne Chaput
发明人： Jean-Louis Junien , Alan Edgar , Evelyne Chaput
IPC分类号： A61K31/216 , A61K31/192 , A61P3/04
CPC分类号： A61K31/192 , A61K31/155 , A61K31/195 , A61K31/216 , A61K2300/00
摘要： The present invention relates to the combined use of a PPARα agonist and metformin for decreasing serum triglycerides.
摘要翻译： 本发明涉及用于降低血清甘油三酸酯的PPARα激动剂和二甲双胍的组合使用。
-
-
-
-
-
-
-
-
-
搜索结果
38 条记录 (耗时 0.033 秒)
